Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm

The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are leading to a shift in both the classification and treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In this trial, T-DXd was associated with a substantial survival benefit among patients with hormone receptor-positive and hormone receptor-negative disease and low expression of HER2, a biomarker previously considered unactionable in this treatment setting. Herein, we discuss the evolving therapeutic pathway for HER2-low disease, ongoing clinical trials, and the potential challenges and evidence gaps arising with treatment of this patient population.

• Publication year

  2023

• Venue

  Therapeutic Advances in Medical Oncology

• Publication date

  2023-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/17588359231175440PMID 37323186PMCID 10262633
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abstract GS2-02: GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

  2023cited by this paper
• Abstract HER2-15: HER2-15 Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatment Patterns, and Outcomes of HER2-Low Breast Cancer

  2023cited by this paper
• Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.

  2023cited by this paper
• The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.

  2023cited by this paper
• Abstract P6-04-03: Computational pathology based HER2 expression quantification in HER2-low breast cancer

  2023cited by this paper
• Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

  2022cited by this paper
• Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.

  2022cited by this paper
• Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.

  2022cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  2022cited by this paper
• Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

  2022cited by this paper
• Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer

  2022cited by this paper
• Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  2022cited by this paper
• 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study

  2022cited by this paper
• LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

  2022cited by this paper
• 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study

  2022cited by this paper
• Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  2022cited by this paper
• Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer

  2022cited by this paper
• Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

  2022cited by this paper
• Clinical significance of HER2-low expression in early breast cancer: a nationwide study from the Korean Breast Cancer Society

  2022cited by this paper
• Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

  2022cited by this paper
• Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.

  2022cited by this paper
• Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)

  2022cited by this paper
• Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study

  2022cited by this paper
• Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.

  2022cited by this paper
• Survival in Women with De Novo Metastatic Breast Cancer: A Comparison of Real-World Evidence from a Publicly-Funded Canadian Province and the United States by Insurance Status

  2022cited by this paper
• Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer

  2022cited by this paper
• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Objective Response to First-Line Treatment as a Predictor of Overall Survival in Metastatic Breast Cancer: A Retrospective Analysis from Two Centers over a 25-Year Period

  2021cited by this paper
• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

  2021cited by this paper
• BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd).

  2021cited by this paper
• Exposure‐Response Relationships in Patients With HER2‐Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan

  2021cited by this paper
• Abstract OT-03-09: Trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator’s choice of chemotherapy in patients with hormone receptor-positive (HR+), HER2 low metastatic breast cancer whose disease has progressed on endocrine therapy in the metastatic setting: A randomized, global phase 3 trial (DES

  2021cited by this paper
• Abstract OT-03-05: Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08)

  2021cited by this paper
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  2021cited by this paper
• Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).

  2020cited by this paper
• HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

  2020cited by this paper
• Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study

  2020cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

  2020cited by this paper
• HER2-Low Breast Cancer: Pathological and Clinical Landscape.

  2020cited by this paper
• Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

  2020cited by this paper
• Systemic therapy for metastatic HER2-positive breast cancer.

  2020cited by this paper
• TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

  2020cited by this paper
• Alpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  2019cited by this paper
• Final analysis of nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.

  2019cited by this paper
• Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

  2019cited by this paper
• NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

  2019cited by this paper
• A population-based analysis of breast cancer incidence and survival by subtype in Ontario women.

  2019cited by this paper
• The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer

  2019cited by this paper
• HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

  2019cited by this paper
• Acquired Resistance to Antibody-Drug Conjugates

  2019cited by this paper
• Cancer in Canada: Stage at diagnosis.

  2018cited by this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cited by this paper
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.

  2018cited by this paper
• A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study

  2018cited by this paper
• Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

  2017cited by this paper
• 308PLower response to T-DM1 in metastatic breast cancer patients with HER2 IHC score of 2 and FISH positive compared with IHC score of 3

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases

  2017cited by this paper
• Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

  2016cited by this paper
• In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases

  2016cited by this paper
• DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

  2016cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

  2015cited by this paper
• Treatment of Metastatic Breast Cancer in a Real-World Scenario: Is Progression-Free Survival With First Line Predictive of Benefit From Second and Later Lines?

  2015cited by this paper
• FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

  2014cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

  2012cited by this paper
• Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

  2011cited by this paper
• Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

  2011cited by this paper
• Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

  2010cited by this paper
• Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

  2007cited by this paper
• [Breast cancer].

  2006cited by this paper
• HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.

  2004cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The National Comprehensive Cancer Network

  1998cited by this paper
• Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

  1990cited by this paper
• Journals

  1989cited by this paper

• HER2 Low and Ultralow Breast Cancer: A Narrative Review of Evolving Classification, Diagnostic Challenges, and Antibody–Drug Conjugate Therapy

  2025cites this paper
• Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type

  2025cites this paper
• Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China

  2025cites this paper
• Updates in Endocrine-Resistant Metastatic Breast Cancer and Treatment-Related Adverse Event Management

  2025cites this paper
• The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy

  2025cites this paper
• Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib

  2025cites this paper
• HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers

  2025cites this paper
• Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus

  2025cites this paper
• Monoclonal Antibodies in Clinical Trials for Breast Cancer Treatment

  2025cites this paper
• Advancing HER2-low breast cancer management: enhancing diagnosis and treatment strategies

  2024cites this paper
• Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy

  2024cites this paper
• Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma

  2024cites this paper
• Strategies for the treatment of hormone receptor-positive HER2-low breast cancer based on clinical practice: a round table discussion

  2024cites this paper
• Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis

  2024cites this paper
• Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial

  2023cites this paper